Phase 3, Double-Blind, Placebo-Controlled Study of MEDI4736 After Chemoradiation in Stage III, Locally Advanced, Unresectable NSCLC (PACIFIC)

被引：0
|
作者：
Cho, Byoung Chul [1 ]
Kim, Joo-Hang [1 ]
Villegas, Augusto [2 ]
Frusch, Nicolas [3 ]
Murakami, Shuji [4 ]
Shi, Kelvin [5 ]
Ibrahim, Ramy [5 ]
Ballas, Marc [5 ]
Antonia, Scott J. [6 ]
机构：
[1] Yonsei Univ Hlth Syst, Severance Hosp, Yonsei Canc Ctr, Seoul, South Korea
[2] Canc Specialists North Florida, Jacksonville, FL USA
[3] Ctr Hosp Ardenne, Libramont, Belgium
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa 2410815, Japan
[5] Astrazeneca, Gaithersburg, MD USA
[6] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; MEDI4736; PD-L1; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-090
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [31] Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
    Earley, Willie
    Burgess, Maria Victoria
    Rekeda, Ludmyla
    Dickinson, Regan
    Szatmari, Balazs
    Nemeth, Gyorgy
    McIntyre, Roger S.
    Sachs, Gary S.
    Yatham, Lakshmi N.
    AMERICAN JOURNAL OF PSYCHIATRY, 2019, 176 (06): : 439 - 448
  • [32] Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
    Goadsby, Peter J.
    Wietecha, Linda A.
    Dennehy, Ellen B.
    Kuca, Bernice
    Case, Michael G.
    Aurora, Sheena K.
    Gaul, Charly
    BRAIN, 2019, 142 : 1894 - 1904
  • [33] Zonisamide improves DLB parkinsonism: A randomized double-blind placebo-controlled phase 3 study
    Murata, M.
    Odawara, T.
    Hasegawa, K.
    Kajiwara, R.
    Takeuchi, H.
    Tagawa, M.
    Kosaka, K.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 185 - 186
  • [34] GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
    Wu, Y-L.
    Zhou, Q.
    Chen, M.
    Jiang, O.
    Hu, D.
    Lin, Q.
    Wu, G.
    Cui, J.
    Chang, J.
    Cheng, Y.
    Huang, C.
    Liu, A.
    Cui, N.
    Wang, J.
    Wang, Q.
    Qin, M.
    Zhang, R.
    Yang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1321 - S1321
  • [35] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [36] Anlotinib as 3rd-Line Treatment for Refractory Advanced NSCLC: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
    Han, Baohui
    Li, Kai
    Zhao, Yizuo
    Li, Baolan
    Cheng, Ying
    Zhou, Jianying
    Lu, You
    Shi, Yuankai
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S177 - S177
  • [37] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
    Weber, Jeffrey
    Thompson, John A.
    Hamid, Omid
    Minor, David
    Amin, Asim
    Ron, Ilan
    Ridolfi, Ruggero
    Assi, Hazem
    Maraveyas, Anthony
    Berman, David
    Siegel, Jonathan
    O'Day, Steven J.
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5591 - 5598
  • [38] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    LANCET ONCOLOGY, 2009, 10 (01): : 25 - 34
  • [39] Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial
    Pouliot, Frederic
    Pantuck, Allan J.
    EUROPEAN UROLOGY, 2009, 55 (06) : 1482 - 1484
  • [40] Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial
    Culp, Stephen H.
    Wood, Christopher G.
    EUROPEAN UROLOGY, 2009, 55 (06) : 1484 - 1485
12345